Edwards Lifesciences (NYSE:EW) Shares Acquired Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently bought shares of Edwards Lifesciences Co. NYSE: EW. In a filing disclosed on May 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Edwards Lifesciences stock on April 7th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
• Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.10 during mid-day trading on Thursday, hitting $76.65. 613,559 shares of the company were exchanged, compared to its average volume of 4,635,552. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a market capitalization of $44.96 billion, a PE ratio of 11.00, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $71.73 and a 200 day moving average of $71.62.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the firm earned $0.66 EPS. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on EW shares. Piper Sandler upped their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday. StockNews.com upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Truist Financial cut their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their target price for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and an average price target of $79.60.

Institutional Trading of Edwards Lifesciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. raised its stake in Edwards Lifesciences by 2.2% in the third quarter. Principal Financial Group Inc. now owns 817,516 shares of the medical research company's stock worth $53,948,000 after buying an additional 17,647 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock worth $824,000 after acquiring an additional 273 shares during the period. Jacobs & Co. CA raised its position in shares of Edwards Lifesciences by 2.3% in the fourth quarter. Jacobs & Co. CA now owns 125,728 shares of the medical research company's stock worth $9,307,000 after acquiring an additional 2,828 shares during the period. Graypoint LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $247,000. Finally, Czech National Bank raised its position in shares of Edwards Lifesciences by 4.2% during the 4th quarter. Czech National Bank now owns 127,881 shares of the medical research company's stock worth $9,467,000 after purchasing an additional 5,166 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the transaction, the chief financial officer now owns 41,098 shares of the company's stock, valued at $3,057,691.20. This trade represents a 21.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This trade represents a 1.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,931 shares of company stock worth $5,148,028 in the last 90 days. Insiders own 1.29% of the company's stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.